Summaries: International Kidney Cancer Symposium
Conclusion: there is no increased risk of doing the lymph node dissection early on.
Dr. Eggener-CON
Basics
Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients. A Mayo study revealed no data showing therapeutic benefit in high risk patients. For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit.
Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...
Source: Kidney Cancer Association - November 29, 2011 Category: Urology & Nephrology Source Type: news
Summaries: International Kidney Cancer Symposium
Conclusion: there is no increased risk of doing the lymph node dissection early on. Dr. Eggener-CON
Basics
Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients. A Mayo study revealed no data showing therapeutic benefit in high risk patients. For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit.
Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nodes. A tumor> 10 cm w...
Source: Kidney Cancer Association - November 29, 2011 Category: Urology & Nephrology Source Type: news
VIDEO: Keyhole Surgery for Kidney Cancer
Laparoscopic radical nephrectomy has almost replaced open surgery as the treatment of choice for kidney cancer.http://www.urologycentre.com.sg/kidney_cancer.html04/20/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 21, 2011 Category: Urology & Nephrology Source Type: news
VIDEO: Keyhole Surgery for Kidney Cancer
Laparoscopic radical nephrectomy has almost replaced open surgery as the treatment of choice for kidney cancer. http://www.urologycentre.com.sg/kidney_cancer.html04/20/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 21, 2011 Category: Urology & Nephrology Source Type: news
VIDEO: Keyhole Surgery for Kidney Cancer
Laparoscopic radical nephrectomy has almost replaced open surgery as the treatment of choice for kidney cancer.http://www.urologycentre.com.sg/kidney_cancer.html04/20/2011 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 21, 2011 Category: Urology & Nephrology Source Type: news
Robotic And Laparoscopic Partial Nephrectomy Without Vascular Clamping And Renal Ischemia
06/18/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 18, 2010 Category: Urology & Nephrology Source Type: news
Robotic And Laparoscopic Partial Nephrectomy Without Vascular Clamping And Renal Ischemia
06/18/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 18, 2010 Category: Urology & Nephrology Source Type: news
AVEO Pharmaceuticals Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorab
< p > AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months. < /p > < p > 06/10/2010 < /p > (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 9, 2010 Category: Urology & Nephrology Source Type: news
New Oral VEGF-TKI, Tivozanib, Demonstrates Robust Anti-tumor Activity and Excellent Safety in Advanced Kidney Cancer Patients Global Phase 3 TIVO-1 Trial Actively Recruiting
AVEO Pharmaceuticals has recently initiated enrollment in a Phase 3 clinical trial evaluating tivozanib– a new oral, once-daily, triple VEGF receptor inhibitor– in patients with advanced kidney cancer, with nearly 500 patients worldwide expected to participate. TIVO-1 is a randomized, controlled trial evaluating tivozanib compared to sorafenib (Nexavar®), an FDA and EMEA approved therapy for the treatment of advanced renal cell carcinoma (RCC). The primary endpoint of the trial is progression-free survival (PFS), while secondary endpoints include overall survival, objective response rate, duration of respon...
Source: Kidney Cancer Association - April 29, 2010 Category: Urology & Nephrology Source Type: news
New Oral VEGF-TKI, Tivozanib, Demonstrates Robust Anti-tumor Activity and Excellent Safety in Advanced Kidney Cancer Patients Global Phase 3 TIVO-1 Trial Actively Recruiting
AVEO Pharmaceuticals has recently initiated enrollment in a Phase 3 clinical trial evaluating tivozanib – a new oral, once-daily, triple VEGF receptor inhibitor – in patients with advanced kidney cancer, with nearly 500 patients worldwide expected to participate. TIVO-1 is a randomized, controlled trial evaluating tivozanib compared to sorafenib (Nexavar®), an FDA and EMEA approved therapy for the treatment of advanced renal cell carcinoma (RCC). The primary endpoint of the trial is progression-free survival (PFS), while secondary endpoints include overall survival, objective response rate, duration of resp...
Source: Kidney Cancer Association - April 29, 2010 Category: Urology & Nephrology Source Type: news
New Oral VEGF-TKI, Tivozanib, Demonstrates Robust Anti-tumor Activity and Excellent Safety in Advanced Kidney Cancer Patients Global Phase 3 TIVO-1 Trial Actively Recruiting
AVEO Pharmaceuticals has recently initiated enrollment in a Phase 3 clinical trial evaluating tivozanib– a new oral, once-daily, triple VEGF receptor inhibitor– in patients with advanced kidney cancer, with nearly 500 patients worldwide expected to participate. TIVO-1 is a randomized, controlled trial evaluating tivozanib compared to sorafenib (Nexavar®), an FDA and EMEA approved therapy for the treatment of advanced renal cell carcinoma (RCC). The primary endpoint of the trial is progression-free survival (PFS), while secondary endpoints include overall survival, objective response rate, duration of respon...
Source: Kidney Cancer Association - April 29, 2010 Category: Urology & Nephrology Source Type: news
